HSDT

Solana Company

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

Solana Company (HSDT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Growth (A-); its weakest is Profitability (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
B
Factor Score 3.2 / 5.0
Growth
A-
Factor Score 3.9 / 5.0
Profitability
D+
Factor Score 1.7 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.3
Rev Growth YoY N/M
Gross Margin 95.5%
Price Return 3M 3.3%
Price Return 12M -65.4%
Catalyst Signal 0.00
Market Cap $121.1M
TTM Revenue $12.1M
Price / Sales 10.0
ROE -179.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 B (3.2) A- (3.9) D+ (1.7) C+ (2.7) C+ (2.5) C+ (2.8)
2026-11-05 B (3.2) A- (3.9) D+ (1.7) B (3.2) C+ (2.6) B- (2.9)
2026-10-29 B- (3.1) A- (3.9) D+ (1.7) B (3.3) C+ (2.5) B- (2.9)
2026-10-22 B- (3.1) A- (3.9) D+ (1.7) B (3.4) C+ (2.5) B- (2.9)
2026-10-15 B- (3.1) A- (3.9) D+ (1.7) B- (3.0) C+ (2.5) C+ (2.8)
Page 1 of 3